Register entry

Arrowhead Pharmaceuticals, Inc.

Data as of · How to read this entry

Registered sites
0
Active NDC listings
1
Live patents
5
Exclusivities
1
Countries
0
Exclusivity

Patents and exclusivities

5
PatentProductCoversExpiry
10294474REDEMPLOplozasiran sodiumsubstance, productMar 2037
11174481REDEMPLOplozasiran sodiumsubstance, productMar 2037
10597657REDEMPLOplozasiran sodiumsubstance, productSept 2038
11214801REDEMPLOplozasiran sodiumsubstance, productSept 2038
12365899REDEMPLOplozasiran sodiumsubstance, productSept 2038
ProductExclusivityUntil
REDEMPLOPLOZASIRAN SODIUMODE-541 Orphan drugNov 2032
Catalogue

Marketed products

1
BrandGeneric nameForm / routeNDC
REDEMPLOplozasiraninjection, solution, subcutaneous84141-025NDA
Enquiry

Common questions

Is Arrowhead Pharmaceuticals, Inc. FDA approved?
Arrowhead Pharmaceuticals, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
What drugs does Arrowhead Pharmaceuticals, Inc. make?
1 product is listed under Arrowhead Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as injection, solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.